Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.52 and traded as high as $0.63. Xtant Medical shares last traded at $0.59, with a volume of 40,675 shares trading hands.
Xtant Medical Trading Up 2.1%
The company has a market capitalization of $87.63 million, a price-to-earnings ratio of -6.99 and a beta of -0.18. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.03 and a current ratio of 2.34. The business's 50-day simple moving average is $0.60 and its 200-day simple moving average is $0.52.
Institutional Investors Weigh In On Xtant Medical
An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC raised its position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 798,033 shares of the medical device company's stock after acquiring an additional 103,825 shares during the period. Renaissance Technologies LLC owned about 0.57% of Xtant Medical worth $354,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 69.33% of the company's stock.
Xtant Medical Company Profile
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
